Blog

Sep 04

Retlirafusp Alfa: A New Approach to Cancer Immunotherapy

By arkonsolutions Blog No Comments

Treatment for a number of cancer types has changed significantly with the development of cancer immunotherapy. However, tumors can employ multiple mechanisms to suppress the immune system and evade immune-mediated…

Aug 27

Love0

Izalontamab Brengitecan (Iza-Bren) Current Development Status, Clinical Progress and Market Outlook in 2026

Izalontamab Brengitecan (Iza-Bren) in 2026: Development, Clinical Progress and Market Outlook

By Dr. Purva Bhandari Blog

Izalontamab brengitecan has emerged as one of the most closely watched next-generation antibody-drug conjugates (ADCs) in solid tumors. Its development has expanded across several difficult-to-treat cancers, including triple-negative breast cancer…

Aug 18

Love0

NMPA Approves Ivonescimab in Combination With Chemotherapy for First-Line Squamous NSCLC

By Dr. Purva Bhandari Blog No Comments

With the advent of new immuno-oncology techniques, the therapy landscape for advanced squamous non-small cell lung cancer (sq-NSCLC) is changing. Regardless of PD-L1 expression, Ivonescimab in combination with chemotherapy was…

Aug 12

Love0

Recombinant Crisantaspase and Its Role in Leukemia and Lymphoblastic Lymphoma Treatment

By Dr. Purva Bhandari Blog No Comments

Chemotherapy frequently uses a number of medications that interact in various ways to treat some blood cancers. Enrylaze (Recombinant Crisantaspase), an enzyme-based drug used in combination chemotherapy for some patients…

Aug 06

Love0

documents needed for named patient program

Which Documents Are Needed for a Named Patient Program?

By Dr. Banisetti Sravya Blog No Comments

Imagine you are finally hearing about a medicine that actually fits into your disease condition. You said yes for the Named Patient Program (NPP) despite you being newly introduced but…

Jun 30

Love1

7 Myths About Named Patient Services That Could Delay Treatment

By Dr. Banisetti Sravya Blog

You are being evaluated thoroughly, you receive an accurate diagnosis, followed by the most appropriate treatment options. You trust your doctor, you have reviewed the medicine. And the reviews say…

Retlirafusp Alfa: A New Approach to Cancer Immunotherapy

Izalontamab Brengitecan (Iza-Bren) in 2026: Development, Clinical Progress and Market Outlook

NMPA Approves Ivonescimab in Combination With Chemotherapy for First-Line Squamous NSCLC

Recombinant Crisantaspase and Its Role in Leukemia and Lymphoblastic Lymphoma Treatment

7 Myths About Named Patient Services That Could Delay Treatment

Recent Posts

Categories

Our Certifications & Accreditations

Stay up to date and
never miss out.

Arkon Solutions

Our Services

Information

Contact Us

Blog

Retlirafusp Alfa: A New Approach to Cancer Immunotherapy

Izalontamab Brengitecan (Iza-Bren) in 2026: Development, Clinical Progress and Market Outlook

NMPA Approves Ivonescimab in Combination With Chemotherapy for First-Line Squamous NSCLC

Recombinant Crisantaspase and Its Role in Leukemia and Lymphoblastic Lymphoma Treatment

Which Documents Are Needed for a Named Patient Program?

7 Myths About Named Patient Services That Could Delay Treatment

Recent Posts

Categories

Our Certifications & Accreditations

Stay up to date and never miss out.

Stay up to date and
never miss out.